Effect of @entity8690 supplementation on resynthesis of XXXX after intense intermittent training in humans.

@entity3211 @entity3625 @entity1989 @entity8690 @entity30975 @entity855
The effect of oral @entity8690 supplementation on the resynthesis of @entity3211 and performance after 1 wk of intense intermittent exercise was examined. Eight subjects performed a random double-blind crossover design. The subjects performed cycle training consisting of 15 x 10 s of all-out sprinting twice per day for 7 days. After training the subjects received either @entity8690 (200 mg/kg body wt; @entity30975 ) or placebo ( @entity1989 ) three times per day for 3 days. An exercise test was performed at 72 h after the last training session. Immediately after the last training session, muscle @entity855 was lowered (P < 0.05) by 25 +/- 2 and 22 +/- 3% in @entity1989 and @entity30975 , respectively. In both @entity1989 and @entity30975 , muscle @entity855 levels at 5 and 24 h after the exercise were still lower (P < 0.05) than pretraining. After 72 h, muscle @entity855 was similar (P > 0.05) to pretraining in @entity30975 (24.6 +/- 0.6 vs. 26.2 +/- 0.2 mmol/kg dry wt) but still lower (P < 0.05) in @entity1989 (21.1 +/- 0.5 vs. 26.0 +/- 0.2 mmol/kg dry wt) and higher (P < 0.05) in @entity30975 than in @entity1989 . Plasma @entity3625 levels after the test performed at 72 h were higher (P < 0.05) in @entity30975 compared with @entity1989 . Mean and peak power outputs during the test performed at 72 h were similar (P > 0.05) in @entity1989 and @entity30975 . The results support the hypothesis that the availability of @entity8690 in the muscle is a limiting factor for the rate of resynthesis of @entity855 . Furthermore, the reduction in muscle @entity855 observed after intense training does not appear to be limiting for high-intensity exercise performance.
